Sarcomatoid hepatocellular carcinoma (SHC) is a rare and aggressive form of liver cancer with a high chance of recurrence after surgical treatment, leading to a poorer prognosis compared to traditional hepatocellular carcinoma (HCC).
A 54-year-old patient with SHC had surgery followed by multiple treatments, including systemic therapies and immunotherapy, but faced recurrent and metastatic disease.
After beginning treatment with nivolumab, an immune checkpoint inhibitor, the patient's metastatic lesions significantly decreased, resulting in 8 months of continuous complete remission.